EuResist update Francesca Incardona Arevir-EuResist International - - PowerPoint PPT Presentation
EuResist update Francesca Incardona Arevir-EuResist International meeting Cologne 8-9 May 2015 EIDB ENGINE RETRAINING ENGINE UPDATE EucoHIV Phylogeotool EuResist Mentor School HCV European database - Pepsi Funding
Arevir-EuResist International meeting Cologne 8-9 May 2015
EIDB ENGINE RETRAINING ENGINE UPDATE EucoHIV Phylogeotool EuResist Mentor School HCV European database - Pepsi Funding opportunities
Presently more than 65000 patients New structure allows to store different
DB management moved from IBM to Koeln Update ongoing In the last two years 2 studies paid by Pharma
Could be better exploited
The EuResist Engine has been trained in
Now it is old:
Short time point (8-12 weeks) Unsatisfactory behaviour with newer drugs
Retraining needed
Retraining is ongoing:
On much larger and newer data set (the present
EIDB)
With longer time point (48 weeks) Lower VL definition for failure: <50 copies per ml Same structure and prediction answer: which
combination therapy will minimise resistance
It will be fit for middle income and emerging
Update is ongoing:
New prediction answer: how long will the patient
remain aviremic
Collaboration among MPS (Alejandro Pironti)
EuResist (Mattia Prosperi) and IBM (Tal El Hay) Other issues may be important: toxicity, pill burden, cost… Clinicians’ comments highly welcome!
Data collection completed: 1470 patients Study proposals are welcome!
From the EucoHIV activities - realised by KuLeuven
group
Will be trained also on the EIDB and offered on the
EuResist Engine website
Skype demo at 4:30 pm today
Clinicians’ comments highly welcome!
Lemey et al. 2009
Multidisciplinary course on value and usage of structured
data
Addressed to young clinicians and researchers Will offer an overview of existing databases and will train
the pupils on how to formulate a scientifically sound question and how to write a query
Based on an extract from EIDB 2 days residential course with follow up possibly leading
to publications
First mid of 2016
Comments highly welcome!
PEPSI is funded from the German Ministry of Science
and Education (BMBF) within the „Deutsches Zentrum für Infektiologische Forschung“, TTU Hepatitis
Andrea De Luca, Maurizio Zazzi and Saleta Sierra
Aragon, Rolf Kaiser performed data evaluation on HCV 1a clade I and II for Italy and Germany (Open Forum in Infectious Diseases, accepted)
We will promote the project through the EURESIST
partners and rise PEPSI on a European level
Phase 1 and Phase 2 18/03/2015 17/06/2015 17/09/2015 25/11/2015
18/03/2015 17/06/2015 18/03/2015 17/06/2015 17/09/2015 25/11/2015 17/09/2015 25/11/2015
Eurostars supports research-performing small and medium enterprises, which develop innovative products, processes and services, to gain competitive advantage. Eurostars provides funding for transnational innovation projects, the products of which are then rapidly commercialized.
To be eligible, the project can address any technology area, but must have a civilian purpose and be aimed at the development of a new product, process or service.
"Improved treatment and clinical management of poverty-related diseases" Close date: moved to 16 June 2015, 17:00 Among the encouraged topics of this Call for Proposals:
drug regimens in humans or to optimise the efficacy and use of existing therapeutics for any of the PRDs, including co-infections of PRDs.
Stage 1 (Letter of Intent) Opening date: 28 January 2015 Deadline for submission: 16 April 2015 - moved to 16 June 2015
http:/ / w w w .euresist.org http:/ / engine.euresist.org Contact: f.incardona@inform acro.info
Innovative Medicines Initiative 2 (IMI 2)